After Merck paid a hefty sum to co-develop and co-commercialize HER3-DXd, the drug has suffered notable setbacks in ...

Patritumab deruxtecan treatment did not improve suvival end points versus those treated with chemotherapy in EGFR+ ...

CHICAGO -- Patients with progressive HER2-positive gastroesophageal (GE) cancer lived significantly longer when they received ...

The Prescription Drug User Fee Act target date has been set for the third quarter of 2025. The Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License Application ...

T-DXd plus pertuzumab can improve outcomes when compared to treatment with a taxane, trastuzumab, and pertuzumab in patients with HER2+ advanced breast cancer.

TROPION-Lung01, evaluating Daiichi Sankyo and AstraZeneca’s datopotamab deruxtecan versus chemotherapy ... a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered ...

Patients received trastuzumab deruxtecan (T-DXd) at a dose of 5.4 mg/kg intravenously every 3 weeks. The primary endpoints were progression-free survival (PFS) for the brain metastases cohort and ...

Datopotamab deruxtecan is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed by Daiichi Sankyo and AstraZeneca.

Aditya Bardia, MD, MPH, FASCO, medical oncologist, UCLA Health, discusses findings from the TROPION-Breast01 study on datapotamab deruxtecan for patients with HR ...

Patritumab deruxtecan is a specifically engineered potential first-in-class HER3-directed DXd antibody-drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed by Daiichi ...

AstraZeneca AZN and Japanese partner Daiichi Sankyo announced that their antibody-drug conjugate, datopotamab deruxtecan (Dato-DXd), failed to achieve statistical significance in the final ...

New analysis of the DESTINY-Breast06 trial demonstrated that trastuzumab deruxtecan (T-DXd) provides meaningful clinical benefit regardless of time to progression on prior endocrine therapy ...